What are the range of options based on NCCN guidelines that should be considered based on the outcome of the biopsy?...

Biopsy Outcomes and Treatment Options for Relapsed/Refractory Follicular Lymphoma

Based on Josh's clinical situation documented in his summary, I need to be clear about what we know and what the upcoming biopsy will help determine.

What the [date removed] Biopsy Will Likely Assess

According to the document, Josh has tissue from a recent splenectomy available for molecular testing. The biopsy will likely evaluate:

1. Disease status confirmation - Whether the progression noted after 8 weeks on the BCL-6 degrader trial represents true progression or treatment effect
2. Molecular/genomic profiling - The document notes that "specific genomic mutations, BRCA status, IHC results, and methylation data [are] not provided in available records," suggesting these tests may be performed on the biopsy tissue
3. BCL-6 pathway involvement - Further characterization of the BCL-6 pathway to guide future targeted therapy decisions

NCCN Guidelines for Relapsed/Refractory Follicular Lymphoma

According to NCCN Guidelines for B-Cell Lymphomas, treatment options for relapsed/refractory follicular lymphoma typically include:

Standard Options:

• Allogeneic stem cell transplantation (which Josh's team has recommended but he is reluctant about)
• Clinical trials with novel agents
• Salvage chemotherapy regimens
• Targeted therapies based on molecular findings

Factors the biopsy results will help determine:

• Whether additional targeted therapy is appropriate based on specific mutations identified
• Eligibility for specific clinical trials based on molecular profile
• Whether the disease remains BCL-6 dependent or has evolved resistance mechanisms

Important Limitations

I should note that the document does not contain Josh's complete molecular profile or specific staging information, which are critical for NCCN treatment recommendations. The biopsy results will be essential for his oncology team to provide personalized guidance based on his specific disease characteristics.

I strongly recommend Josh discuss the biopsy results directly with his oncology team, as they can correlate the molecular findings with NCCN Guidelines and his individual clinical circumstances to determine the most appropriate next steps.

Would you like me to clarify any aspects of what the biopsy might reveal or how it connects to his treatment options?